Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

Core Viewpoint - Editas Medicine, Inc. announced a partial affirmation and partial vacate of a previous decision by the U.S. Court of Appeals regarding patent interference related to CRISPR/Cas9 editing, with the case remanded back to the Patent Trial and Appeal Board (PTAB) for further review [1] Group 1: Legal and Patent Developments - The U.S. Court of Appeals for the Federal Circuit has affirmed-in-part and vacated-in-part the PTAB's decision regarding patents for CRISPR/Cas9 editing in human cells involving the University of California, University of Vienna, Emmanuelle Charpentier, and the Broad Institute [1] - Editas Medicine's in-licensed patents covering CRISPR/Cas12a are not affected by this decision and are not involved in the ongoing interference proceedings [1] Group 2: Company Strategy and Intellectual Property - The company remains confident in the strength of its intellectual property (IP) portfolio, which is expected to generate significant value now and in the future [2] - Editas holds a large portfolio of foundational U.S. and international patents, including exclusive licenses for Cas9 and Cas12a patent estates, which are crucial for developing human medicines [2] - The foundational IP includes issued patents covering fundamental aspects of CRISPR/Cas12a and CRISPR/Cas9 gene editing in all human cells, essential for CRISPR-based medicines [2] Group 3: Company Mission and Focus - Editas Medicine is focused on translating the potential of CRISPR/Cas12a and CRISPR/Cas9 systems into a pipeline of in vivo medicines for serious diseases [3] - The company aims to discover, develop, manufacture, and commercialize transformative gene editing medicines for a broad class of diseases [3]